Ribociclib Series

Ribociclib Series
Product Description

a cyclin-dependent kinase (CDK) inhibitor that targets cyclin D1/CDK4 and cyclin D3/CDK6 at nanomolar concentrations. It inhibits retinoblastoma protein phosphorylation, which prevents CDK-mediated G1-S phase transition, arresting the cell cycle in the G1 phase, suppressing DNA synthesis, and inhibiting cancer cell growth. LEE011 has been shown to reduce proliferation in 12 of 17 human neuroblastoma-derived cell lines by inducing cytostasis (mean IC50 = 306 nM in sensitive lines).

Read more Show less

Tianjin Pharmacn Medical Technology Co., Ltd.

  • CN
  • 2015
    On CPHI since
  • 2
    Certificates
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Intermediates Manufacturer
View company profile
Categories
more categories Show less
Specifications
  • CAS Registry Number
    1211441-98-3
  • Details
    Boiling point:730.8±70.0 °C(Predicted)Density：1.39±0.1 g/cm3(Predicted)
    vapor pressure: 0-0Pa at 20-25℃ 
    storage temp： -20°C
    solubility： Soluble in DMSO (up to 10 mg/ml)
    pka：8.67±0.10(Predicted)
    form: solid
    color： Off-white
    MF: C23H30N8O 
    MW:434.54 
    EINECS:807-111-0
  • Selling Points
    International Approvals/Standards; Price; Prompt Delivery; Quality Service; Reputation; Small Orders Accepted; Sustainability; Products will not be supplied to countries in which they would be in conflict with the valid patents and will only be offered to the R&D projects.
  • Supplied from
    China
  • Measured In
    kilogram
More specifications Fewer specifications
Sales Markets
Show more Show less

Tianjin Pharmacn Medical Technology Co., Ltd.

  • CN
  • 2015
    On CPHI since
  • 2
    Certificates
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Intermediates Manufacturer
View company profile

More Products from Tianjin Pharmacn Medical Technology Co., Ltd. (14)

  • N-(4-(2-aminoacetyl)-5-methoxy-2-phenoxyphenyl)methanesulfonamide hydrochloride

    Product N-(4-(2-aminoacetyl)-5-methoxy-2-phenoxyphenyl)methanesulfonamide hydrochloride

    Tianjin pharmacn medical technology co ltd offers apis, pharmaceutical intermediates and fine chemicals . Contact us for more information.
  • MethanesulfonaMide, N-[4-[2-(forMylaMino)acetyl]-5-hydroxy-2-phenoxyphenyl]-

    Product MethanesulfonaMide, N-[4-[2-(forMylaMino)acetyl]-5-hydroxy-2-phenoxyphenyl]-

    Tianjin pharmacn medical technology co ltd offers apis, pharmaceutical intermediates and fine chemicals . Contact us for more information.
  • 2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]-benzonitrile

    Product 2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]-benzonitrile

    Intermediate in the preparation of poly (ADP-ribose) polymerase (PARP) inhibitors.
  • 2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyriMidine-6-carboxylic acid

    Product 2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyriMidine-6-carboxylic acid

    Raw materials Ribociclib intermediate
  • 2-Chloro-7-cyclopentyl-N,N-dimethyl-H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

    Product 2-Chloro-7-cyclopentyl-N,N-dimethyl-H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

    Tianjin pharmacn medical technology co ltd offers apis, pharmaceutical intermediates and fine chemicals . Contact us for more information.
  • Palbociclib Series

    Product Palbociclib Series

    Palbociclib is a Kinase Inhibitor. The mechanism of action of palbociclib is as a Kinase Inhibitor, and Cytochrome P450 3A Inhibitor.
  • Cabozantinib Series

    Product Cabozantinib Series

    Cabozantinib was approved in November 2012 for the treatment of patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Cabozantinib was granted orphan drug status by the FDA to facilitate development of newtreatment options for patients with MTC. It is a me...
  • Iguratimod Series

    Product Iguratimod Series

    Iguratimod is a disease modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Preclinical in vivo studies indicated that iguratimod was effective in an established adjuvant-induced arthritis model (ED40=3.6 mg/kg) in rats and also efficacious in a type II collagen-induced ar...
  • Dexmedetomidine hydrochloride Series

    Product Dexmedetomidine hydrochloride Series

    Dexmedetomidine was launched in the US as an i.v. infusion for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care unit, This imidazole derivative is the (S)-enantiomer of medetomidine that can be obtained via fractional crystallization of the tartrate...
  • Fluorometholone Series

    Product Fluorometholone Series

    Fluorometholone is the topical synthetic glucocorticoid. Its tropical anti-inflammatory effect is 40 times as much as hydrocortisone, but their effects of oral administration are almost equal. It is mainly used for local treatment of skin allergy, pruritus, rash and other diseases related to allergy. Oral ...
  • Linezolid Series

    Product Linezolid Series

    Linezolid is for the treatment of patients with infections caused by serious Gram-positive pathogens, particularly skin and soft tissue infections, communityacquired pneumonia and vancomycin-resistant enterococcal infections. Linezolid is the (S)-enantiomer of an oxazolidin-2-one synthesized in a multistep...
  • Cisatracurium Besylate Series

    Product Cisatracurium Besylate Series

    Cisatracurium besylate is a new intermediate-duration non-depolarizing muscle relaxant launched in the U.S.A. for intubation and maintenance of muscle relaxation during surgery and intensive care. Cisatracurium besylate is the single 1 R cis-1'R cis isomer of the commercial preparation of atracurium, a mix...
show all 14 other products

Tianjin Pharmacn Medical Technology Co., Ltd. resources (2)

  • Product Brochure

    Brochure Product Brochure

    Tianjin pharmacn medical technology co ltd offers Apis, pharmaceutical intermediates and fine chemicals. Contact us for more information.
  • 2023 CPHI Shanghai Fair

    Video 2023 CPHI Shanghai Fair

    Tianjin pharmacn medical technology co ltd offers apis, pharmaceutical intermediates and fine chemicals. Contact us for more information.
    2023-06-28